Stories
Early CAR-T Referral Crucial for Better Cancer Outcomes in India
N
News18•21-09-2026, 17:45
Early CAR-T Referral Crucial for Better Cancer Outcomes in India
- •India's first indigenous CAR-T therapy, NexCAR19, is transforming advanced cancer treatment, prompting new decisions for physicians on patient referral timing and safety.
- •Dr. Anusha Swaminathan emphasizes that CAR-T therapy yields better outcomes when patients are referred early, before their disease significantly deteriorates, and when they are physically fit.
- •The safety profile of indigenous CAR-T therapies like NexCAR19 is encouraging, with manageable toxicities such as cytokine release syndrome (CRS) and rare neurotoxicity (ICANS).
- •CAR-T is a 'living therapy' requiring ongoing monitoring for infections and blood count fluctuations; careful patient selection and multidisciplinary team support are vital for success.
- •Early evaluation by a CAR-T team is critical, allowing for proactive planning and identifying the optimal treatment window, even if immediate therapy isn't required.
Key Questions Answered
India's first indigenous CAR-T therapy is called NexCAR 19, which has transitioned advanced cancer treatment into real-world clinical practice for relapsed and refractory blood cancers.
CAR-T therapy works best when patients are referred before becoming too unwell, as lower disease burden, better physical fitness, and less prior organ damage lead to superior treatment outcomes.
The primary toxicities monitored include cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and immune effector cell-associated hemophagocytic syndrome (IEC-HS).
